This report provides an analysis of Europe’s clinical trial compensation for investigator payments across 18 therapeutic areas, 5 compound types, and the 4 phases of development. It provides pharmaceutical, biotech, and service providers an opportunity to gain a better understanding of what drives investigator payments so they can benchmark their payment levels and better plan for study costs.

1. EW
PR
EV
I
Benchmarking European
Investigator Payments
Info@ISRreports.com
©2014 Industry Standard Research
www.ISRreports.com

2. act with confidence
Report Overview
This report provides an analysis of Europe’s clinical trial compensation for investigator payments across 18
therapeutic areas, 5 compound types, and the 4 phases of development. It provides pharmaceutical, biotech,
and service providers an opportunity to gain a better understanding of what drives investigator payments so
they can benchmark their payment levels and better plan for study costs.
Methodologies:
Germany = 40 respondents
France = 39 respondents
Eastern Europe = 20 respondents
UK = 43 respondents
ISR conducted 142 online quantitative surveys with respondents who
•
•
•
Currently work at a research site
… are located in Western or Eastern Europe
… have responsibility for investigator payments
312
Charts and Graphs
104
Pages
Q1,
2014
Publication Date
Report Structure:
1. Executive Summary
2. Benchmarking Investigator Fees
•
•
•
•
Phase comparison by specialty/therapeutic area
Compound type compensation by specialty/therapeutic area
Region/ country comparison by phase
Region/ country comparison by compound type
3. Investigator Payment Dynamics
• Understand what motivates investigators to participate in clinical trials and where
compensation falls in the rankings. ISR presents respondents with clinical trial scenarios
and asks how investigator fee requirements would need to change as inclusion/exclusion
criteria, visit frequency, and difficulty of test schedule are varied.
4. Profiled Specialty/Therapeutic Area
5. Site and Respondent Demographics
Therapeutic Areas Evaluated:
• Analgesic/Pain
Management
• Cardiovascular
• CNS
• Dermatology
• Gastrointestinal
•
•
•
•
•
Hematology
Infectious Diseases
Internal Medicine
Metabolic Diseases
Musculoskeletal/
Arthritis
•
•
•
•
•
Oncology
Ophthalmology
Orthopedics
Pediatric
Respiratory/Allergy/
Pulmonology
• Urology
• Vaccines
• Women’s Health
Compound Types Included:
• Biologic
• Biosimilar
• Me-too
• Generic
• Novel
www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments
2

3. act with confidence
What you will learn in this report:
•
•
•
•
Average compensation investigators receive per subject for each therapy area by phase
and compound orientation/ type
How study characteristics (length and complexity) change fee levels
What motivates investigators to participate in a trial
Therapeutic area profiles
How you can use this report:
•
•
•
Optimize your investigator payments across therapeutic areas, phases of development,
compound type under investigation, and geography
Establish and better negotiate investigator payments
Use “trial complexity” and “length of study” as variables to create more accurate budget
projections and lower costs
Valuable for:
•
•
•
•
•
•
Project Management
Clinical Operations
Outsourcing
Trial Budgeting
Feasibility
CRO Proposals
Up next: Full table of contents and sample pages
www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments
3

4. act with confidence
Table of Contents
For table of contents and additional sample pages, please download the full preview from our website:
http://bit.ly/1dpPqGd
www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments
4

5. act with confidence
Sample Page: Report Introduction
Introduction
act with confidence
Introduction
One way to to ISR’s the Russian clinical trial and pharmaceutical environment is
Welcome think aboutsecond Investigator Payments report
to think of the
highlightingcountry as a publically tradedpresentation, youcompany� If a comEurope’s clinical trial pharmaceutical would find you were
compensation. In this
leafing through a prospectus or an investor
report, ISR wanted fundamentals, historicunderstanding of what
pany with strong macro to gain a better growth, inconsistent performance,
and some regulatory uncertainty� In short, that has many of the same characterdrives investigator payments so Russiasponsors and CROs can
istics as a mid-stage pharmaceutical company�
you take a portfolio theory
benchmark their paymentlikely want to And, if some portion of your assets
levels and better plan for study costs.
approach to investing, you would
invest
in Russia� Why?
Determinants of investigator payments come in many forms
↑ Macroeconomics: Russia is the world’s 10th largest economy
such as therapeutic area, compound orientation, trial complexity,
↑ patient needs. Is there the World Trade Organization (WTO) in 2012
andInternational recognition: Joineda one-size-fits-all formula that
↑ be applied sheet: Russia has ~$240B trade to produce the reserves
canPositive balanceuniformly across studiessurplus from fossil fuelmost
↑ Focus: compensation plan? Perhaps not, but medicines this
effective Putin announced $3�9B plan aimed at having 90% ofby using to be
locally produced by 2020
array of compensation averages provided by site personnel
↑ by understanding their non-monetary motivations for trial
andReimbursement structure: Medicines Insurance System (Aug 2012) is to be in
place by 2020 that will include a
participation, ISR believes a tiered rate of reimbursement, depending on
sponsor or CRO can recruit and
the nature of the illness, and improve access to medications
retain high quality sites without breaking the budget.
↑ Growth: Russian pharmaceutical market has been growing 17% annually since
2005
↑ Untapped potential: Many patients are treatment naïve, offering opportunities
for clinical trial patient recruitment
↓ Uncertainty: Regulatory environment and customs practices are unstable and
unpredictable
↓ Difficult: In 2012 the World Bank ranked Russia 122nd on their list of economies
by ease of doing business, 21 spots below China
↓ Skills: Finding highly qualified healthcare professionals can be difficult
↓ Protection: IP protection is concerning
www.ISRreports.com ©2013 | Russia: Clinical Development Country Profile
7
www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments
5

6. act with confidence
Sample Page
Introduction
act with confidence
Average Compensation per Patient by Therapeutic Area and Phase
Only therapeutic areas with 4 or more responses in a phase are included in the
following sections.
In terms of investigator highest compensation for Phase ranked as II-IV, Internal
Internal Medicine had the payment fees, only oncology I. For Phase one of the
top three most below average compensation.
Medicine receivedexpensive therapeutic area across phase II, III, and IV of
development.
Oncology received the highest compensation for Phase II and the third highest
compensation for Phase III and Phase IV. Oncology received below average
compensation for Phase I.
Phase I
Phase II
Phase Pediatric did not IV
Phase
Pediatric received the highest compensation for Phase III compounds. III
receive enough responses to be reported in the other phases.
Highest
Oncology
Analgesic / Pain
Compensation Management received the highest compensation for Phase IV. In all
($7,676)
other phases, analgesic / pain management fell below average for compensation.
Second
Highest
Ophthalmology received the second highest average compensation for Phase I and
Data available in full report
Phase III. Ophthalmology did not receive enough responses for Phase II or Phase IV.
Third Highest
Average
Phase I
Phase II
Phase III
Phase IV
Highest
Compensation
Internal
Medicine
($12,125)
Oncology
($7,676)
Pediatric
($11,200)
Analgesic
/ Pain
Management
($5,000)
Second
Highest
Ophthalmology
($7,750)
Third Highest
Vaccines
($6,750)
Musculoskeletal/
Arthritis ($5,071)
Oncology
($7,136)
Oncology
($2,591)
Average
$5,529
$4,159
$4,604
$2,441
Metabolic
Ophthalmology
Diseases ($5,333)
($7,250)
Hematology
($4,000)
©2014 Industry Standard Research
www.ISRreports.com ©2014 | Benchmarking European Investigator Payments
15
www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments
6

7. act with confidence
Sample Page
For table of contents and additional sample pages, please download the full preview from our website:
http://bit.ly/1dpPqGd
www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments
7

8. act with confidence
Ordering Information
For pricing and ordering information, please visit our website:
http://bit.ly/1dpPqGd
About Industry Standard Research
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma
and pharma services industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.
For more information about our off-the-shelf intelligence and custom research offerings, please visit
our Web site at www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.
www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments
8

9. The ISR Difference
act with confidence
Custom-quality syndicated market research
www.ISRreports.com
ISR's Reports
vs.
The Common
Syndicated Report
How confident are you?
Research methods
Mostly primary
research;
always appropriate
for the topic
vs.
vs.
One size fits all;
usually publically
available data
Data Collection
ISR's proprietary data collection
tools and channels support fast,
high quality data collection
vs.
Struggle to recruit the right
targets and enough of them
Respondents
Sophisticated screening
ensures genuine
decision-makers
vs.
Undisclosed
methodologies and
respondent demographics
Sample Sizes
Robust sample sizes that
instill confidence
vs.
Often insufficient industry
representation that leaves you
defending results
Analysts
Decades of experience
means more insights that are
immediately usable
vs.
vs.
Junior analysts capable of
reporting numbers
www.ISRreports.com ©2013©2014 | Preview of: Benchmarking European Investigator Functions
www.ISRreports.com | Preview of: Benchmarking the Pharma Industry’s HEOR Payments
9